XML 41 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock Options and Stock Appreciation Rights
12 Months Ended
Dec. 31, 2024
Stock Options and Stock Appreciation Rights  
Stock Options and Stock Appreciation Rights

(14) Stock Options and Stock Appreciation Rights

On April 5, 2012, the Board of Directors adopted the 2012 International Bancshares Corporation Stock Option Plan (the “2012 Plan”). There were 800,000 shares of common stock available for stock option grants under the 2012 Plan, which were qualified incentive stock options (“ISOs”) or non-qualified stock options. Options granted may be exercisable for a period of up to 10 years from the date of grant, excluding ISOs granted to 10% shareholders, which may be exercisable for a period of up to only five years. On April 4, 2022, the 2012 Plan expired and was not renewed.

The fair value of each option award granted under the plan was estimated on the date of grant using a Black-Scholes-Merton option valuation model that uses the assumptions noted in the following table. Expected volatility was based on the historical volatility of the price of our stock. We used historical data to estimate the expected dividend

yield and employee termination rates within the valuation model. The expected term of options was derived from historical exercise behavior. The risk-free rate for periods within the contractual life of the option was based on the U.S. Treasury yield curve in effect at the time of grant.

A summary of option activity under the stock option plans for the twelve months ended December 31, 2024 is as follows:

    

    

    

Weighted

    

    

Weighted

average

average

remaining

Aggregate

Number of

exercise

contractual

intrinsic

options

price

term (years)

value ($)

(in Thousands)

Options outstanding at December 31, 2023

 

383,865

$

30.65

Plus: Options granted

 

Less:

Options exercised

 

(149,773)

25.08

Options expired

 

Options forfeited

 

(21,937)

23.93

Options outstanding at December 31, 2024

 

212,155

 

35.27

 

4.13

$

5,918

Options fully vested and exercisable at December 31, 2024

 

121,714

$

35.92

 

3.31

$

3,316

Stock-based compensation expense included in the consolidated statements of income for the years ended December 31, 2024, 2023, and 2022 was approximately $214,000, $330,000, and $449,000, respectively. As of December 31, 2024, there was approximately $218,000 of total unrecognized stock-based compensation cost related to non-vested options granted under our plans that will be recognized over a weighted average period of 1.4 years.

Other information pertaining to option activity during the twelve months ended December 31, 2024, 2023, and 2022 is as follows:

Twelve Months Ended December 31,

 

2024

2023

2022

 

Weighted average grant date fair value of stock options granted

    

$

    

$

    

$

11.24

Total fair value of stock options vested

$

616,286

$

514,000

$

514,000

Total intrinsic value of stock options exercised

$

4,640,000

$

1,060,000

$

1,670,000

On April 18, 2022, the Board of Directors adopted the 2022 International Bancshares Stock Appreciation Rights Plan (the “SAR Plan”). There are 750,000 shares of underlying common stock that may be used for stock appreciation right (“SAR”) grants under the plan, however, no actual shares will be granted. Upon exercise, the SAR will be settled in cash. SARs granted may be exercisable for a period of up to 10 years from the date of grant and may vest over an eight-year period. As of December 31, 2024, a total of 456,702 SARS had been issued under the SAR Plan.

A summary of activity under the SAR Plan for the twelve months ended December 31, 2024 is as follows:  

    

    

    

Weighted

    

    

Weighted

average

Number of

average

remaining

Aggregate

stock appreciation

exercise

contractual

intrinsic

rights

price

term (years)

value ($)

(in Thousands)

SARs outstanding at December 31, 2023

 

465,250

$

39.35

Plus: SARs granted

 

8,000

53.91

Less:

SARs exercised

 

(2,548)

39.33

SARs expired

 

SARs forfeited

 

(14,000)

39.33

SARs outstanding at December 31, 2024

 

456,702

 

39.61

 

7.54

$

10,757

SARs fully vested and exercisable at December 31, 2024

 

22,435

$

39.35

 

7.50

$

534

The fair value of the liability for payments due to stock appreciation rights holders at December 31, 2024 and December 31, 2023 is approximately $4,540,000 and $1,464,000, respectively, as calculated using a Black-Scholes-Merton model, and is included in other liabilities on the consolidated statements of condition. The expense recorded in connection with all grants under the SAR Plan totaled $3,144,000, $918,000 and $546,000, respectively, for the twelve months ended December 31, 2024, 2023, and 2022. As of December 31, 2024, there was approximately $8,309,000 in unrecognized liability related to non-vested SARs granted under the plan that will be recognized over a weighted average period of 7.5 years.